Indivior PLC, together with its subsidiaries, develops, manufactures, and sells buprenorphine-based prescription drugs for the treatment of opioid dependence. More Details
Reasonable growth potential with mediocre balance sheet.
Share Price & News
How has Indivior's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: INDV's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: INDV exceeded the UK Pharmaceuticals industry which returned 3.9% over the past year.
Return vs Market: INDV exceeded the UK Market which returned -14.8% over the past year.
Price Volatility Vs. Market
How volatile is Indivior's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 week ago | Simply Wall StIs Indivior (LON:INDV) A Risky Investment?
2 months ago | Simply Wall StCan You Imagine How Indivior's (LON:INDV) Shareholders Feel About The 90% Share Price Increase?
7 months ago | Simply Wall StAuditors Are Concerned About Indivior (LON:INDV)
Is Indivior undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: INDV (£1.04) is trading below our estimate of fair value (£9.32)
Significantly Below Fair Value: INDV is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: INDV is unprofitable, so we can't compare its PE Ratio to the GB Pharmaceuticals industry average.
PE vs Market: INDV is unprofitable, so we can't compare its PE Ratio to the UK market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate INDV's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: INDV is overvalued based on its PB Ratio (17x) compared to the GB Pharmaceuticals industry average (4.5x).
How is Indivior forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: INDV is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.2%).
Earnings vs Market: INDV is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: INDV's is expected to become profitable in the next 3 years.
Revenue vs Market: INDV's revenue (9.7% per year) is forecast to grow faster than the UK market (6% per year).
High Growth Revenue: INDV's revenue (9.7% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if INDV's Return on Equity is forecast to be high in 3 years time
How has Indivior performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: INDV is currently unprofitable.
Growing Profit Margin: INDV is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: INDV is unprofitable, and losses have increased over the past 5 years at a rate of 19.9% per year.
Accelerating Growth: Unable to compare INDV's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: INDV is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (9.8%).
Return on Equity
High ROE: INDV has a negative Return on Equity (-262.07%), as it is currently unprofitable.
How is Indivior's financial position?
Financial Position Analysis
Short Term Liabilities: INDV's short term assets ($1.2B) exceed its short term liabilities ($684.0M).
Long Term Liabilities: INDV's short term assets ($1.2B) exceed its long term liabilities ($809.0M).
Debt to Equity History and Analysis
Debt Level: INDV's debt to equity ratio (406.9%) is considered high.
Reducing Debt: INDV had negative shareholder equity 5 years ago, but is now positive and has therefore improved.
Debt Coverage: INDV's operating cash flow is negative, therefore debt is not well covered.
Interest Coverage: INDV is unprofitable, therefore interest payments are not well covered by earnings.
What is Indivior current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate INDV's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate INDV's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if INDV's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if INDV's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: INDV is not paying a notable dividend for the UK market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of INDV's dividend in 3 years as they are not forecast to pay a notable one for the UK market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Mr. Mark Crossley has been Chief Executive Officer of Indivior PLC since June 29, 2020 and served as its Chief Financial and Operations Officer since July 29, 2019 until June 29, 2020. He was Chief Financ ...
CEO Compensation Analysis
Compensation vs Market: Mark's total compensation ($USD0.00) is below average for companies of similar size in the UK market ($USD1.15M).
Compensation vs Earnings: Mark's compensation has been consistent with company performance over the past year.
|CEO & Executive Director||0.33yr||US$550.80k||0.047% |
|Interim CFO and Senior VP of Global Financial Planning & Analysis Commercial Operations||0.33yr||no data||no data|
|Chief Scientific Officer||no data||no data||0.060% |
|Vice President of Investor Relations||no data||no data||no data|
|Chief Legal Officer||no data||no data||0.058% |
|Chief Integrity & Compliance Officer||2yrs||no data||no data|
|Chief Human Resources Officer||6yrs||no data||0.034% |
|Chief Commercial & Strategy Officer||no data||no data||0.083% |
|Senior Vice President of Global Clinical Development||no data||no data||no data|
|Chief Manufacturing & Supply Officer||0.58yr||no data||no data|
|Company Secretary||5.33yrs||no data||no data|
Experienced Management: INDV's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.
|CEO & Executive Director||0.33yr||US$550.80k||0.047% |
|Independent Non-Executive Director||0.92yr||no data||0.0068% |
|Independent Non-Executive Director||5.92yrs||no data||0.015% |
|Independent Non-Executive Director||1.17yrs||no data||0.0074% |
|Interim Independent Chairman of the Board & Senior Independent Director||0.33yr||no data||0.0018% |
|Independent Non-Executive Director||5.92yrs||no data||0.0035% |
|Independent Non-Executive Director||5.92yrs||no data||0.0010% |
Experienced Board: INDV's board of directors are considered experienced (3.7 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Indivior PLC's company bio, employee growth, exchange listings and data sources
- Name: Indivior PLC
- Ticker: INDV
- Exchange: LSE
- Founded: 2014
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: UK£762.845m
- Shares outstanding: 733.50m
- Website: https://www.indivior.com
Number of Employees
- Indivior PLC
- 10710 Midlothian Turnpike
- North Chesterfield
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|INDV||LSE (London Stock Exchange)||Yes||Ordinary Shares||GB||GBP||Dec 2014|
|INDVL||BATS-CHIXE (BATS 'Chi-X Europe')||Yes||Ordinary Shares||GB||GBP||Dec 2014|
|IZQV.F||OTCPK (Pink Sheets LLC)||Yes||Ordinary Shares||US||USD||Dec 2014|
|INDV N||BMV (Bolsa Mexicana de Valores)||Yes||Ordinary Shares||MX||MXN||Dec 2014|
|INVV.Y||OTCPK (Pink Sheets LLC)||SPONSORED ADR||US||USD||Dec 2014|
|2IVA||DB (Deutsche Boerse AG)||SPONSORED ADR||DE||EUR||Dec 2014|
Indivior PLC, together with its subsidiaries, develops, manufactures, and sells buprenorphine-based prescription drugs for the treatment of opioid dependence. The company’s product pipeline focuses on trea ...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/10/20 22:20|
|End of Day Share Price||2020/10/20 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.